• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Impact of FDG PET in small-cell lung cancer patients treated with curative intent chemoradiotherapy

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Salem, Ahmed
    Abravan, Azadeh
    Sandhu, L.
    Faivre-Finn, Corinne
    Abutaleb, Khalid
    Crockett, Cathryn
    Price, Gareth J
    Affiliation
    University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Purpose or Objective The role of staging 18F-fludeoxyglucose PET/CT in small-cell lung cancer (SCLC) is uncertain (not mandated in the CONVERT trial with discrepancy in clinical guidelines). We investigated the impact of 18F-fludeoxyglucose PET/CT on survival in SCLC patients treated with curative-intent chemoradiotherapy. Materials and Methods Patients with limited-disease (TNM stage 1-3) histologically confirmed SCLC who received curative-intent chemoradiotherapy in a single UK institution between 2015 and 2018 were retrospectively analysed. Patients were divided into 2 groups: those staged with conventional imaging (contrast-enhanced thorax and abdomen CT and brain imaging with or without bone scintigraphy) and those staged with 18F-fludeoxyglucose PET/CT in addition. The primary endpoint was overall survival. Univariable and multivariable Cox analyses were conducted to evaluate the following variables for association with survival: age, gender, baseline comorbidities, Eastern Cooperative Oncology Group performance status (ECOG PS), TNM stage, planning target volume (PTV), use of staging 18F-fludeoxyglucose PET/CT and treatment approach (sequential vs concurrent chemoradiotherapy). The study was approved locally and complied with UK research governance (ethics reference: 17/NW/0060). Results Data from 203 patients with limited-disease SCLC were analysed. Median overall survival in the whole cohort was 19.1 months (range: 1.8-78.1). Median overall survival was 14.9 months (range: 1.8-77.6) and 37.7 months (range: 1.9-78.1) in patients treated with sequential (radiotherapy dose: 50-55Gy in 20 once daily fractions; 140 (69%) patients) and concurrent chemoradiotherapy (radiotherapy dose: 45Gy in 30 twice daily fractions; 63 (31%) patients), respectively. The two staging groups were well balanced (including treatment approach) except for a higher percentage of patients with ECOG PS2, a lower percentage of patients with N3 stage and slightly smaller PTV volume in patients staged with 18F-fludeoxyglucose PET/CT (p<0.05; Table 1A). Variables associated with overall survival on multivariable analysis were male gender (HR=1.49; 95% CI: 1.05-2.10, p=0.025), N2 stage (HR=2.00; 95% CI: 1.10-3.65, p=0.024), sequential chemoradiotherapy (HR=1.94, 95% CI: 1.30-2.90, p=0.001) and staging 18F-fludeoxyglucose PET/CT (HR=0.59, 95% CI: 0.41-0.86, p=0.006) as seen in Table 1b. Median overall survival was 23.6 months (range: 1.8-78.1) and 15.0 months (range: 3.1-77.6) in patients staged with or without 18F-fludeoxyglucose PET/CT, respectively (Kaplan Meier survival curves adjusted for variables in the multivariable model are shown. Conclusion We report longer overall survival in limited-stage SCLC patients who were staged with 18F-Fludeoxyglucose PET/CT. While prospective trials are needed for confirmation, our results provide indirect evidence supporting the use of staging 18F Fludeoxyglucose PET/CT in SCLC patients considered for curative intent chemoradiotherapy.
    Citation
    Salem A, Abravan A, Sandhu L, Faivre-Finn C, Abutaleb M, Crockett C, et al. Impact of FDG PET in small-cell lung cancer patients treated with curative intent chemoradiotherapy. Radiotherapy and Oncology. 2022 May;170:S605-S7. PubMed PMID: WOS:000806764200239.
    Journal
    Radiotherapy and Oncology
    URI
    http://hdl.handle.net/10541/625520
    Type
    Meetings and Proceedings
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.